Neuroendocrine Tumor (NET) Surgery | Pancreatic & Gastrointestinal NET Multidisciplinary Care

Pancreatic diseases require careful integration of imaging interpretation, tumor biology, pancreatic ductal anatomy, and multidisciplinary care. This section reflects a focused hepatopancreatobiliary (HPB) surgical oncology practice dedicated to complex pancreatic conditions including pancreatic cancer, pancreatic cystic neoplasms, neuroendocrine tumors, and chronic pancreatitis.

Neuroendocrine Tumor Surgery in the Context of Grade, Molecular Biology, and Receptor Expression

Neuroendocrine tumors (NETs) are biologically heterogeneous neoplasms arising from hormone-producing neuroendocrine cells distributed throughout the pancreas and gastrointestinal tract.

Unlike pancreatic ductal adenocarcinoma and other conventional gastrointestinal malignancies, NETs are defined by a combination of:

  • Tumor grade (Ki-67 index)

  • Differentiation status

  • Somatostatin receptor expression

  • Molecular alterations

  • Hormone production profile

Effective management therefore requires more than anatomic staging. It demands integration of tumor biology, receptor imaging, systemic therapy options, and surgical judgment within a coordinated multidisciplinary program.

As a fellowship-trained robotic surgical oncologist and hepatopancreatobiliary (HPB) surgeon serving the San Francisco Bay Area, Dr. Geoffrey W. Krampitz specializes in complex pancreatic and gastrointestinal NET surgery, including:

  • Pancreatic neuroendocrine tumor (PNET) resection

  • Small intestinal NET resection with mesenteric lymphadenectomy

  • Cytoreductive hepatic surgery in selected metastatic cases

  • Combined pancreatic and vascular resections when biologically appropriate

Management of neuroendocrine tumors has been a sustained academic focus throughout Dr. Krampitz’s surgical and research training, including prior investigative work examining molecular determinants of tumor progression. This translational perspective informs a treatment philosophy grounded in both operative precision and biologic understanding.

Care is delivered within a structured multidisciplinary framework integrating surgical oncology, medical oncology, endocrinology, nuclear medicine, interventional radiology, and advanced imaging — consistent with tertiary neuroendocrine tumor center standards.

For comparison with pancreatic adenocarcinoma management, see Pancreatic Cancer Surgery.

Biological Foundations of Neuroendocrine Tumors

Neuroendocrine cells regulate physiologic processes through peptide hormone secretion, including:

  • Glucose metabolism

  • Gastric acid production

  • Digestive enzyme release

  • Intestinal motility

Neoplastic transformation results in tumors that may be indolent, hormonally active, metastatic at presentation, or biologically aggressive — depending on grade and differentiation.

NETs most commonly arise in the:

  • Pancreas

  • Small intestine

  • Stomach

  • Rectum

Tumor Classification: Function, Grade, and Molecular Risk Stratification

Functional vs. Non-Functional NETs

Functional NETs produce bioactive hormones that generate clinical syndromes such as:

  • Insulinoma (hypoglycemia)

  • Gastrinoma (Zollinger–Ellison syndrome)

  • Glucagonoma

  • Carcinoid syndrome

Non-functional NETs do not produce clinically apparent hormonal syndromes and are often diagnosed incidentally or due to mass effect.

Tumor Grade and Proliferation Index

Tumor grade is determined by mitotic count and Ki-67 proliferation index:

  • Grade 1 (Ki-67 <3%) – indolent

  • Grade 2 (Ki-67 3–20%) – intermediate

  • Grade 3 (Ki-67 >20%) – biologically aggressive

Grade remains one of the most important determinants of prognosis, metastatic potential, and treatment sequencing.

Distinguishing Well-Differentiated Grade 3 NET from Neuroendocrine Carcinoma (NEC)

It is essential to distinguish well-differentiated Grade 3 NETs from poorly differentiated neuroendocrine carcinomas (NECs). Although both may demonstrate a Ki-67 index greater than 20%, they represent biologically distinct entities.

Well-differentiated Grade 3 NETs retain neuroendocrine architecture and somatostatin receptor expression and may remain candidates for surgery, somatostatin analog therapy, targeted therapy, or PRRT depending on disease distribution.

In contrast, poorly differentiated NECs (small cell or large cell subtype) exhibit high proliferative activity, genomic instability (commonly including TP53 and RB1 alterations), and aggressive clinical behavior. These tumors are typically managed with platinum-based systemic chemotherapy, with surgery reserved for highly selected localized presentations.

Accurate pathologic classification — including morphologic review, Ki-67 assessment, immunohistochemistry, and molecular context — is critical to appropriate sequencing.

Telomere Biology, Epigenetics, and Emerging Molecular Risk Layers

Beyond proliferative index and differentiation, telomere maintenance mechanisms and epigenetic alterations are increasingly recognized as determinants of metastatic behavior.

Pancreatic NETs frequently harbor alterations in:

  • MEN1

  • DAXX

  • ATRX

  • mTOR pathway components (e.g., TSC2, PTEN)

Loss of DAXX or ATRX expression is associated with activation of the alternative lengthening of telomeres (ALT) pathway, linked to chromosomal instability and increased metastatic potential.

Epigenetic dysregulation, including chromatin remodeling abnormalities and methylation shifts, may further contribute to biologic heterogeneity among tumors with similar Ki-67 indices.

Small intestinal NETs demonstrate distinct molecular patterns and frequently exhibit strong somatostatin receptor subtype 2 (SSTR2) expression, central to both imaging and peptide receptor radionuclide therapy (PRRT).

While molecular profiling does not replace established grading systems, integration of telomere biology, pathway-level alterations, and receptor expression patterns represents an evolving framework for personalized sequencing within tertiary NET programs.

For broader biomarker-driven strategy, see Molecular Oncology & Surgical Strategy.

Intratumoral Heterogeneity and Clonal Evolution

Neuroendocrine tumors may demonstrate intratumoral proliferative heterogeneity, with variation in Ki-67 index between different regions of the same tumor and between primary and metastatic sites. Sampling bias may therefore underestimate biologic aggressiveness.

Emerging data suggest that NETs may undergo clonal evolution over time, acquiring additional genomic alterations that influence grade, receptor expression, and therapeutic responsiveness. Re-biopsy of progressive disease is sometimes warranted to reassess differentiation and proliferation index.

Recognition of this heterogeneity reinforces the importance of multidisciplinary interpretation when determining surgical timing and systemic sequencing.

Advanced Imaging and Receptor Characterization

Accurate evaluation integrates anatomic and functional imaging.

Cross-Sectional Imaging

  • CT or MRI of the abdomen and pelvis

  • CT of the chest

Somatostatin Receptor Imaging

  • DOTATATE PET/CT

DOTATATE PET/CT provides high-sensitivity detection of well-differentiated NETs through SSTR2 targeting and plays a central role in staging, operative planning, and PRRT candidacy assessment.

Somatostatin receptor expression, particularly SSTR2 density, is a critical determinant of PRRT eligibility; loss of receptor expression in higher-grade transformation may alter candidacy and sequencing strategy.

Staging and Metastatic Disease

The liver is the most common site of distant metastasis.

In selected patients with well-differentiated, liver-dominant disease, cytoreductive hepatic surgery may provide durable disease control when integrated with systemic therapy.

For hepatic resection strategies, see Liver Cancer Surgery.

Treatment Strategy: Grade-Driven, Biology-Informed Sequencing

Management decisions depend on:

  • Tumor grade and differentiation

  • Disease distribution

  • Hormonal activity

  • Receptor expression

  • Molecular alterations

Contemporary management may include:

  • Surgical resection

  • Somatostatin analog therapy

  • Targeted therapy (mTOR pathway inhibition)

  • Peptide receptor radionuclide therapy (PRRT)

  • Liver-directed therapies

  • Observation in selected low-grade tumors

The objective is durable disease control through biology-driven sequencing rather than reflexive intervention.

All cases are evaluated through structured multidisciplinary review.

Surgical Management of NETs

Surgery remains the cornerstone of treatment for localized, well-differentiated NETs when complete oncologic resection can be achieved safely.

Pancreatic Neuroendocrine Tumors (PNETs)

Operative options may include:

  • Enucleation for selected small tumors

  • Distal pancreatectomy

  • Pancreaticoduodenectomy (Whipple procedure)

Extent of resection is determined by tumor size, grade, ductal proximity, nodal risk, vascular anatomy, and overall safety.

For broader pancreatic context, see Pancreatic Cancer Surgery.

Small Intestinal NETs

Standard treatment includes:

  • Segmental small bowel resection

  • Formal mesenteric lymphadenectomy

  • Careful management of mesenteric fibrosis

Complex mesenteric dissection may be required in advanced presentations.

Gastric Neuroendocrine Tumors

Gastric NETs are categorized into:

  • Type I – Associated with chronic atrophic gastritis and hypergastrinemia

  • Type II – Associated with gastrinoma and MEN1

  • Type III – Sporadic, non-hypergastrinemic, and more aggressive

Management depends on tumor type, grade, and invasion depth. Small Type I lesions may be managed endoscopically, whereas larger or Type III tumors often require formal oncologic resection.

Accurate classification integrating gastrin levels, endoscopic findings, grade, and receptor expression is essential for appropriate sequencing.

Robotic and Minimally Invasive NET Surgery

When anatomically appropriate, NET surgery may be performed using advanced robotic-assisted techniques.

Robotic platforms provide:

  • High-definition magnified visualization

  • Articulated instrumentation

  • Refined mesenteric and retroperitoneal dissection

Technology does not supersede oncologic discipline.
Operative platform selection is guided by tumor biology, grade, vascular anatomy, and safety.

Learn more in Robotic Surgery.

Programmatic Expertise and Tertiary NET Care

NET management often spans years and may involve staged interventions and systemic therapy transitions.

Why experience matters in NET surgery:
Outcomes are closely associated with expertise in complex pancreatic and mesenteric anatomy, receptor-guided therapy integration, molecular interpretation, and longitudinal disease management — core components of tertiary neuroendocrine tumor programs.

Care is delivered within an experienced HPB-focused practice aligned with multidisciplinary standards typical of tertiary NET centers.

Genetic and Hereditary Syndromes

Hereditary syndromes include:

  • Multiple Endocrine Neoplasia type 1 (MEN1)

  • Von Hippel–Lindau syndrome (VHL)

  • Neurofibromatosis type 1 (NF1)

Genetic findings may influence surveillance, operative timing, and family screening.

Multidisciplinary Neuroendocrine Tumor Care

Optimal management requires collaboration among:

  • Surgical oncology

  • Medical oncology

  • Endocrinology

  • Nuclear medicine

  • Interventional radiology

  • Radiology and pathology

  • Nutrition and supportive care

Treatment sequencing aligns surgery, receptor-targeted therapy, systemic treatment, and surveillance with tumor biology.

Consultation and Referral

For Patients:
Individuals seeking evaluation for pancreatic or gastrointestinal neuroendocrine tumors may Request a Consultation to discuss individualized strategy.

For Referring Physicians:
Physicians wishing to refer a patient or discuss complex NET management may visit For Physicians for direct referral pathways and coordinated case review.